--- page 1 ---
1
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange ”)
and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no responsibility for the contents of this
announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability
whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those
defined in the prospectus dated June 12, 2026 (the “Prospectus ”) issued by HJ Science Co., Ltd. ( ശ਄͊Ը (ϓே)߅
ʮ̡ ) (the “Company ”).
This announcement is for information purposes only and does not constitute an offer or an invitation to induce an
offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a
prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global
Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in
relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.
This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States
(including its territories and possessions, any state of the United States and the District of Columbia). This
announcement does not, and is not intended to, constitute or form a part of any offer to sell or solicitation to purchase
or subscribe for any securities in the United States or in any other jurisdiction. The Offer Shares have not been,
and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “U.S.
Securities Act ”) or securities law of any state or other jurisdiction of the United States and may not be offered,
sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from,
or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with
any applicable state securities laws. The Offer Shares are being offered and sold solely outside the United States in
offshore transactions in reliance on Regulation S under the U.S. Securities Act. There will be no public offer of the
Offer Shares in the United States.
In connection with the Global Offering, CLSA Limited, as stabilizing manager (the “Stabilizing Manager ”), or any
person acting for it, on behalf of the Underwriter, may over-allocate or effect transactions with a view to stabilizing
or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited
period after the Listing Date. However, there is no obligation on the Stabilizing Manager (or any person acting for it)
to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the
Stabilizing Manager (or any person acting for it) and may be discontinued at any time. Any such stabilizing action is
required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong
Public Offering. Such stabilizing action, if taken, may be effected in all jurisdictions where it is permissible to do so,
in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and
Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities
and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).
Potential investors of the Offer Shares should note that the Sole Overall Coordinator (acting in such capacity and as the
Hong Kong Underwriter) shall be entitled to terminate its obligations under the Hong Kong Underwriting Agreement
with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting –
Underwriting Arrangements and Expenses – Hong Kong Public Offering – Hong Kong Underwriting Agreement –
Grounds for Termination ” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which
is currently expected to be on Tuesday, June 23, 2026).


--- page 2 ---
2
HJ Science Co., Ltd.
ശ਄͊Ը (ϓே)ʮ̡
(A joint stock company incorporated in the People ’s Republic of China with limited liability)
GLOBAL OFFERING
Number of Offer Shares under the Global
Offering
: 13,600,000 H Shares (subject to the Over-
allotment Option)
Number of Hong Kong Offer Shares : 1,360,000 H Shares
Number of International Offer Shares : 12,240,000 H Shares (subject to the Over-
allotment Option)
Offer Price : HK$81.80 per Offer Share, plus brokerage
of 1.0%, SFC transaction levy of
0.0027%, Stock Exchange trading fee of
0.00565%, and AFRC transaction levy of
0.00015%
Nominal Value : RMB1.00 per Share
Stock Code : 6132
Sole Sponsor, Sponsor-Overall Coordinator, Sole Overall Coordinator, Sole Global
Coordinator, Sole Bookrunner and Sole Lead Manager


--- page 3 ---
3

HJ SCIENCE CO., LTD. / 華健未來（成都）科技股份有限公司
ANNOUNCEMENT OF ALLOTMENT RESULTS
Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings
as those defined in the Prospectus issued by the Company.
Warning: In view  of high  concentration of shareholding in a small number of Shareholders,
Shareholders and prospective investors should be aware that the price of the H Shares could move
substantially even with a small number of H Shares traded and should exercise extreme caution when
dealing in the H Shares.
SUMMARY

Company information
Stock code  6132
Stock short name  HJ SCIENCE-B
Dealings commencement date  June 23, 2026*
*see note at the end of the announcement
Price Information
Offer Price  HK$81.80

Offer Shares and Share Capital
Number of Offer Shares (before exercise of Over-allotment
Option)
13,600,000 H Shares
Final Number of Offer Shares in Hong Kong Public
Offering
1,360,000 H Shares
Final Number of Offer Shares in International Offering
(before exercise of Over-allotment Option)
12,240,000 H Shares
Number of issued shares upon Listing (before exercise of
Over-allotment Option)
73,599,605 Shares

Over-allocation
Number of Offer Shares over-allocated 2,040,000 H Shares

Such over -allocation may be covered by exercising the Over -allotment Option or by making purchases in the
secondary market at prices that do not exceed the Offer Price or through deferred delivery or a combination of these
means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange’s
website.
Proceeds
Gross proceeds (Note)  HK$1,112.5 million
Less: Estimated listing expenses payable based on Offer
Price
HK$93.7 million
Net proceeds  HK$1,018.7 million
Note: Gross proceeds refers to the amount to which the  Company is entitled to receive. For details of the
use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus.
Any discrepancies in the table between the aggregate amount and the sums of individual amounts listed
therein are due to rounding.


--- page 4 ---
4

ALLOTMENT RESULTS DETAILS
HONG KONG PUBLIC OFFERING

No. of valid applications  173,284
No. of successful applications  13,418
Subscription level  2,007.60 times
Reallocation N/A
No. of Offer Shares initially available under the Hong Kong Public
Offering
1,360,000
No. of Offer Shares reallocated from the International Offering N/A
Final no. of Offer Shares under the Hong Kong Public Offering 1,360,000
% of Offer Shares under the Hong Kong Public Offering to the
Global Offering (before exercise of Over-allotment Option)
10.00%

Note: For details of the final allocation of H Shares to the Hong Kong Public Offering, investors can refer to
www.eipo.com.hk/eIPOAllotment to perform a search by identification number or
www.eipo.com.hk/eIPOAllotment for the full list of allottees.
INTERNATIONAL OFFERING

No. of placees  91
Subscription Level 7.00 times
No. of Offer Shares initially available under the International
Offering
12,240,000
Final no. of Offer Shares under the International Offering (before
exercise of Over-allotment Option)
12,240,000
% of Offer Shares under the International Offering to the Global
Offering (before exercise of Over-allotment Option)
90.00%

The Directors confirm that, to the best of their knowledge, information and belief, save for consent under
paragraph 1C(2) of Appendix F1 to the Listing Rules , (i) none of the Offer Shares subscribed by the placees
and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors,
chief executive of the Company, substantial Shareholders, existing Shareholders of the Company or any of its
subsidiaries or their respective close associates; and (ii) none of the placees and the public who have
purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors,
Supervisors, chief executive of the Company, substantial Shareholders, existing Shareholders of the Company
or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or
other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.
The placees in the International Offering include the following:


--- page 5 ---
5

Cornerstone Investors
Investor Note 1
No. of
Offer
Shares
allocated
% of Offer
Shares
(assuming the
Over-allotment
Option is not
exercised)
% of total
issued share
capital after
the
Global
Offering
(assuming the
Over-
allotment
Option is not
exercised)

Existing
shareholders
or
their close
associates
Foresight Global Superior Choice
SPC — Global Superior Choice
Fund 1 SP, Foresight Global
Superior Choice SPC — Vision
Fund 1 SP, Foresight Global
Superior Choice SPC — Horizon
Fund 1 SP, Foresight Global
Superior Choice SPC — Horizon
Next Fund SP and Foresight
International Series — Foresight
China Equity Fund (collectively,
“Foresight Funds”)
2,395,400   17.61% 3.25% No
Key Broad Future Limited (凱博
未來有限公司) (“Key Broad”)
             2,395,400  17.61% 3.25% No
LBC HK Opportunity Fund
Limited (“LBC HK”)
                479,000  3.52% 0.65% No
Sage Partners Master Fund
(“Sage Partners”)
                383,200  2.82% 0.52% No
Panjing Harbourview Investment
Fund (盤京港景投資基金)
(“Panjing Fund”)
                287,400  2.11% 0.39% No
Taikang Life Insurance Co., Ltd.
(泰康人壽保險有限責任公司)
(“Taikang Life”)
                287,400  2.11% 0.39% No
Total 6,227,800 45.79% 8.46%
Notes:
1. For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors” in
the Prospectus.


--- page 6 ---
6

Allotees with Consents Obtained
Investor
No. of Offer
Shares
allocated
% of Offer Shares
(assuming the
Over-allotment
Option is not
exercised)
% of total issued
share capital after
the Global
Offering
(assuming the
Over-allotment
Option is not
exercised)

Relationship
Allotees with consents under paragraph 1C(1) of Appendix F1 to the Listing Rules (the "Placing Guidelines") in
relation to allocations to connected clients Note 1
CITIC Securities
International Capital
Management
Limited ("CSI")
213,000  1.57%  0.29%  Connected client as a
placee
Shanxi Securities
International
Asset Management
Limited ("SSIAM")
244,400 1.80%  0.33%  Connected client as a
placee
Allottee with consent under paragraph 1C(2) of the Placing Guidelines in relation to allocation to a close associate
of existing Shareholders
Wealth Shine Asia
Pacific Limited
("Wealth Shine")
Note 2
96,800 0.71%  0.13%  A close associate of
existing
Shareholders
Notes:
1. For details of the consent s under paragraph 1C (1) of the Placing Guidelines in relation to allocations to
connected clients, please refer to the section headed “Others / Additional Information – Placing to connected
clients with prior consents under paragraph 1C(1) of the Placing Guidelines” in this announcement.

2. Ruiji Phase III Venture Capital Partnership (Limited  Partnership) (安義瑞吉三期創業投資合夥企業(有限合
夥)) (“Ruiji Phase III”) and Anyi Ruiji Phase X Venture Capital Partnership Enterprise (Limited Partnership)
(安義瑞吉十期創業 投資合夥企業  (有限合夥 ) ("Ruiji Phase X ") own approximately 1.72% and 1.11%,
respectively, of the total number of issued Shares of the Company before the Global Offering. Such shareholding
is expected to be approximately 2.44% immediately following the completion of the Global Offering (and before
any exercise of the Over-allotment Option), after taking into account the Shares to be subscribed by Wealth Shine
under the International Offering.  For further details, please refer to the section headed " Others / Additional
Information – Placing to a close associate of existing Shareholder s as placee with a prior consent under
paragraph 1C(2) of the Placing Guidelines" in this announcement.


LOCK-UP UNDERTAKINGS
Controlling Shareholders
Name
Number of Shares
held in the Company
subject to lock-up
undertakings
immediately upon
Listing
% of shareholding in
the Company subject
to lock-up
undertakings upon
Listing (assuming the
Over-allotment
Last day subject to the
lock-up undertakings
Note 2


--- page 7 ---
7

Option is not
exercised)
Dr. Ji Jianxin (姬建新) (“Dr. Ji”)
Note 1
12,424,624 16.88% June 22, 2027
Chengdu Wenshao Enterprise
Management Center (Limited
Partnership) (成都聞韶企業管理
中心(有限合夥)) (“Chengdu
Wenshao”) Note 1
19,971,379 27.14% June 22, 2027
Suzhou Jishitang Enterprise
Management Center (Limited
Partnership) (蘇州積石堂企業管
理中心(有限合夥)) (“Suzhou
Jishitang”) Note 1
2,097,440 2.85% June 22, 2027
Total  34,493,443 46.87%
Notes:
1. Dr. Ji, Chengdu Wenshao and Suzhou Jishitang will be regarded as a group of Controlling Shareholders upon
Listing. For further details, please refer to “Relationship with our Controlling Shareholders” in the Prospectus.

2. The expiry date of the lock -up period shown in the table above is pursuant to the PRC Company Law. In
accordance with the relevant Listing Rules/guidance materials, the required lock-up for existing Shareholders
ends on June 22, 2027, being 12 months following the Listing Date.

Cornerstone Investors
Name
Number of Shares
held in the
Company subject to
lock-up
undertakings upon
Listing
% of shareholding in
the Company subject
to lock-up
undertakings upon
Listing (assuming
the Over-allotment
Option is not
exercised)
Last day subject to the
lock-up undertakings Note
2
Foresight Funds 2,395,400   3.25% December 22, 2026
Key Broad              2,395,400  3.25% December 22, 2026
LBC HK                  479,000  0.65% December 22, 2026
Sage Partners                  383,200  0.52% December 22, 2026
Panjing Fund                  287,400  0.39% December 22, 2026
Taikang Life                 287,400  0.39% December 22, 2026
Total  6,227,800 8.46%


--- page 8 ---
8

Name
Number of Shares
held in the
Company subject to
lock-up
undertakings upon
Listing
% of shareholding in
the Company subject
to lock-up
undertakings upon
Listing (assuming
the Over-allotment
Option is not
exercised)
Last day subject to the
lock-up undertakings Note
2
Notes:
1. In accordance with the relevant cornerstone investment agreements, the required lock-up ends on December
22, 2026. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares
subscribed for pursuant to the relevant cornerstone investment agreements after the indicated date.

Pre-IPO Investors (as defined in the "History, Development and Corporate Structure" section of the
Prospectus)
Name
Number of shares held in
the Company subject to
lock-up undertakings
upon listing
% of shareholding in the
Company subject to lock-up
undertakings upon listing
(assuming the Over-
allotment Option is not
exercised)
Last day subject to the lock-
up undertakings Note 1
(SDIC) VC Fund (Shanghai) of
Technology Transfer and
Commercialization (Limited
Partnership) (國投(上海)科技成
果轉化創業投資基金企業(有限
合夥))
           5,520,100  7.50% June 22, 2027
Suzhou Junlian Xinkang Venture
Capital Partnership (Limited
Partnership) (蘇州君聯欣康創
業投資合夥企業(有限合夥))
           4,246,253  5.77% June 22, 2027
Chongqing Jiangjin District
Private Equity Investment Fund
Partnership (Limited
Partnership) (重慶市江津區私
募股權投資基金合夥企業(有限
合夥))
           2,222,218  3.02% June 22, 2027
Chongqing Chengyu Tuanjie
Lake Strategic Emerging
Industry Private Equity
Investment Fund Partnership
(Limited Partnership) (重慶市成
渝團結湖戰略性新興產業私募
1,777,751 2.42% June 22, 2027


--- page 9 ---
9

Name
Number of shares held in
the Company subject to
lock-up undertakings
upon listing
% of shareholding in the
Company subject to lock-up
undertakings upon listing
(assuming the Over-
allotment Option is not
exercised)
Last day subject to the lock-
up undertakings Note 1
股權投資基金合夥企業(有限合
夥))
Ningbo Huaige Ruixin Venture
Capital Partnership Enterprise
(Limited Partnership) (寧波懷格
銳信創業投資合夥企業(有限合
夥))
1,617,322 2.20% June 22, 2027
Shanghai Junshi Biosciences
Co., Ltd. (上海君實生物醫藥科
技股份有限公司)
1,261,749 1.71% June 22, 2027
Chengdu Peikun Jingrong
Venture Capital Partnership
(Limited Partnership) (成都沛坤
菁蓉創業投資合夥企業(有限合
夥))
1,204,357 1.64% June 22, 2027
Anyi Ruiji Phase III Venture
Capital Partnership (Limited
Partnership) (安義瑞吉三期創
業投資合夥企業(有限合夥))
1,032,356 1.40% June 22, 2027
Sichuan Science and Technology
Achievement Transformation
Equity Investment Fund
Partnership (Limited
Partnership) (四川省科技成果
轉化股權投資基金合夥企業(有
限合夥))
946,326 1.29% June 22, 2027
Xiamen Jianfa Emerging
Industries Equity Investment
Partnership No. 2 (Limited
Partnership) (廈門建發新興產
業股權投資貳號合夥企業(有限
合夥))
876,544 1.19% June 22, 2027
Zhang Naiye (張乃燁) 876,544 1.19% June 22, 2027
Hefei Xingtai Huike Venture
Capital Partnership (Limited
Partnership) (合肥興泰慧科創
業投資合夥企業(有限合夥))
666,671 0.91% June 22, 2027


--- page 10 ---
10

Name
Number of shares held in
the Company subject to
lock-up undertakings
upon listing
% of shareholding in the
Company subject to lock-up
undertakings upon listing
(assuming the Over-
allotment Option is not
exercised)
Last day subject to the lock-
up undertakings Note 1
Anyi Ruiji Phase X Venture
Capital Partnership Enterprise
(Limited Partnership) (安義瑞吉
十期創業投資合夥企業(有限合
夥))
666,662 0.91% June 22, 2027
Suzhou Yuanju Fanmao
Investment Partnership
Enterprise (Limited Partnership)
(蘇州元聚帆茂投資合夥企業
(有限合夥))
606,591 0.82% June 22, 2027
Chengdu Chunlei Xingming
Technology Venture Capital
Partnership Enterprise (Limited
Partnership) (成都春壘星溟科
技創業投資合夥企業(有限合
夥))
499,997 0.68% June 22, 2027
Wuxi Runyuan
Biopharmaceutical Venture
Capital Partnership (Limited
Partnership) (無錫潤元生物醫
藥創業投資合夥企業(有限合
夥))
444,467 0.60% June 22, 2027
Fuzhou Huace Xinming
Pharmaceutical Investment
Partnership Enterprise (Limited
Partnership) (福州華策新明醫
藥投資合夥企業(有限合夥))
444,442 0.60% June 22, 2027
Hefei Baohe District Linghang
Venture Capital Fund
Partnership Enterprise (Limited
Partnership) (合肥市包河區領
航創業投資基金合夥企業(有限
合夥))
444,442 0.60% June 22, 2027
Ningbo Huaige Health
Investment Management
Partnership (Limited
Partnership) (寧波懷格健康投
資管理合夥企業(有限合夥))
103,212 0.14% June 22, 2027


--- page 11 ---
11

Name
Number of shares held in
the Company subject to
lock-up undertakings
upon listing
% of shareholding in the
Company subject to lock-up
undertakings upon listing
(assuming the Over-
allotment Option is not
exercised)
Last day subject to the lock-
up undertakings Note 1
Chengdu Peikun Songfu
Technology Partnership (Limited
Partnership) (成都沛坤宋富科
技合夥企業(有限合夥))
48,158 0.07% June 22, 2027
Total 25,506,162 34.66%
Notes:
1. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.


--- page 12 ---
12

PLACEE CONCENTRATION ANALYSIS

Placees* Number of
H Shares
allotted
Allotment as %
of International
Offering
(assuming the
Over-allotment
Option is not
exercised)
Allotment as %
of International
Offering
(assuming the
Over-allotment
Option is
exercised and
new H Shares are
issued)
Allotment as %
of total Offer
Shares (assuming
the Over-
allotment Option
is not exercised)
Allotment as % of
total Offer Shares
(assuming the
Over-allotment
Option is
exercised and
new H Shares are
issued)
Number of
Shares held upon
Listing
% of total issued
share capital
upon Listing
(assuming the
Over-allotment
Option is not
exercised)
% of total issued
share capital
upon Listing
(assuming the
Over-allotment
Option is
exercised and
new H Shares
are issued)
Top 1 2,395,400  19.57% 16.77% 17.61% 15.32%  2,395,400  3.25% 3.17%
Top 5 7,576,000  61.90% 53.05% 55.71% 48.44%  7,576,000  10.29% 10.02%
Top 10 10,449,000  85.37% 73.17% 76.83% 66.81%  10,449,000  14.20% 13.81%
Top 25 13,001,900  106.22% 91.05% 95.60% 83.13%  14,700,918  19.97% 19.44%

Note
* Ranking of placees is based on the number of H Shares allotted to the placees.

H SHAREHOLDERS CONCENTRATION ANALYSIS

H
Shareholders*
Number of H
Shares
allotted
Allotment as
% of
International
Offering
(assuming the
Over-
allotment
Option is not
exercised)
Allotment as
% of
International
Offering
(assuming the
Over-
allotment
Option is
exercised and
new H Shares
are issued)
Allotment as
% of total
Offer Shares
(assuming the
Over-
allotment
Option is not
exercised)
Allotment as
% of total
Offer Shares
(assuming the
Over-
allotment
Option is
exercised and
new H Shares
are issued)
Number of H
Shares held
upon Listing
% of total
issued H
Share capital
upon Listing
(assuming the
Over-
allotment
Option is not
exercised)
% of total
issued H share
capital upon
Listing
(assuming the
Over-
allotment
Option is
exercised and
new H Shares
are issued)
Number of
Shares held
upon Listing

Top 1 -    0.00% 0.00% 0.00% 0.00% 34,493,443  46.87% 45.60% 34,493,443
Top 5 2,395,400  19.57% 16.77% 17.61% 15.32% 50,655,165  68.83% 66.97% 50,655,165
Top 10 4,887,600  39.93% 34.23% 35.94% 31.25% 59,525,648  80.88% 78.70% 59,525,648
Top 25 10,545,800  86.16% 73.85% 77.54% 67.43% 70,100,963  95.25% 92.68% 70,100,963

Note
* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.


--- page 13 ---
13


SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders* Number of H
Shares allotted
Allotment as
% of
International
Offering
(assuming the
Over-allotment
Option is not
exercised)
Allotment as
% of
International
Offering
(assuming the
Over-allotment
Option is
exercised and
new H Shares
are issued)
Allotment as
% of total
Offer Shares
(assuming the
Over-allotment
Option is not
exercised)
Allotment as
% of total
Offer Shares
(assuming the
Over-allotment
Option is
exercised and
new H Shares
are issued)
Number of H
Shares held
upon Listing
Number of
Shares held
upon Listing

% of total
issued Share
capital upon
Listing
(assuming the
Over-allotment
Option is not
exercised)
% of total
issued share
capital upon
Listing
(assuming the
Over-allotment
Option is
exercised and
new H Shares
are issued)
Top 1 -    0.00% 0.00% 0.00% 0.00% 34,493,443  34,493,443  46.87% 45.60%
Top 5 2,395,400  19.57% 16.77% 17.61% 15.32% 50,655,165  50,655,165  68.83% 66.97%
Top 10 4,887,600  39.93% 34.23% 35.94% 31.25% 59,525,648  59,525,648  80.88% 78.70%
Top 25 10,545,800  86.16% 73.85% 77.54% 67.43% 70,100,963  70,100,963  95.25% 92.68%

Note
* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.


--- page 14 ---
14

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the
public will be conditionally allocated on the basis set out below:

    APPROXIMATE
PERCENTAGE
ALLOTTED OF
THE TOTAL NO.
OF SHARES
APPLIED FOR

NO. OF SHARES
APPLIED FOR
NO. OF VALID
APPLICATIONS


BASIS OF ALLOTMENT / BALLOT

POOL A

100 81,913  1,638 out of 81,913 to receive 100 Shares 2.00%
200 8,450  215 out of 8,450 to receive 100 Shares 1.27%
300 4,357  128 out of 4,357 to receive 100 Shares 0.98%
400 2,851  93 out of 2,851 to receive 100 Shares 0.82%
500 3,371  118 out of 3,371 to receive 100 Shares 0.70%
600 12,470  467 out of 12,470 to receive 100 Shares 0.62%
700 1,814  72 out of 1,814 to receive 100 Shares 0.57%
800 1,076  45 out of 1,076 to receive 100 Shares 0.52%
900 874  38 out of 874 to receive 100 Shares 0.48%
1,000 8,505  381 out of 8,505 to receive 100 Shares 0.45%
1,500 2,514  130 out of 2,514 to receive 100 Shares 0.34%
2,000 2,125  121 out of 2,125 to receive 100 Shares 0.28%
2,500 1,454  90 out of 1,454 to receive 100 Shares 0.25%
3,000 1,418  93 out of 1,418 to receive 100 Shares 0.22%
3,500 1,009  70 out of 1,009 to receive 100 Shares 0.20%
4,000 1,259  92 out of 1,259 to receive 100 Shares 0.18%
4,500 920  70 out of 920 to receive 100 Shares 0.17%
5,000 1,991  157 out of 1,991 to receive 100 Shares 0.16%
6,000 1,587  133 out of 1,587 to receive 100 Shares 0.14%
7,000 1,367  121 out of 1,367 to receive 100 Shares 0.13%
8,000 1,191  111 out of 1,191 to receive 100 Shares 0.12%
9,000 942  91 out of 942 to receive 100 Shares 0.11%
10,000 5,288  531 out of 5,288 to receive 100 Shares 0.10%


--- page 15 ---
15

20,000 3,418  438 out of 3,418 to receive 100 Shares 0.06%
30,000 2,480  366 out of 2,480 to receive 100 Shares 0.05%
40,000 1,710  279 out of 1,710 to receive 100 Shares 0.04%
50,000 1,387  245 out of 1,387 to receive 100 Shares 0.04%
60,000 2,484  467 out of 2,484 to receive 100 Shares 0.03%

160,225

Total number of Pool A successful applicants:
6,800



POOL B

70,000 4,235

1,503 out of 4,235 to receive 100 Shares 0.05%
80,000 1,293  493 out of 1,293 to receive 100 Shares 0.05%
90,000 748  304 out of 748 to receive 100 Shares 0.05%
100,000 2,337  1,007 out of 2,337 to receive 100 Shares 0.04%
150,000 1,188  638 out of 1,188 to receive 100 Shares 0.04%
200,000 836  526 out of 836 to receive 100 Shares 0.03%
250,000 511  363 out of 511 to receive 100 Shares 0.03%
300,000 360  282 out of 360 to receive 100 Shares 0.03%
350,000 203  173 out of 203 to receive 100 Shares 0.02%
400,000 206  189 out of 206 to receive 100 Shares 0.02%
450,000 109  107 out of 109 to receive 100 Shares 0.02%
500,000 204
100 Shares plus 7 out of 204 to receive additional
100 Shares 0.02%
600,000 137
100 Shares plus 20 out of 137 to receive
additional 100 Shares 0.02%
680,000 692
100 Shares plus 155 out of 692 to receive
additional 100 Shares 0.02%

13,059

Total number of Pool B successful
applicants: 6,618


As of the date of this announcement, the relevant subscription monies previously deposited in the designated
nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should
contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE
The Directors confirm that, except  for the Listing Rules in  respect of which  consents have been


--- page 16 ---
16

obtained, the Company has complied with the Listing Rules and guidance materials in relation to
the placing, allotment and listing of the Company’s H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the
public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by
them was the  same as the Offer Price in addition to any brokerage, AFRC transaction levy, SFC
transaction levy and Stock Exchange trading fee payable.

OTHERS / ADDITIONAL INFORMATION

Placing to connected clients with prior consents under paragraph 1C(1) of the Placing Guidelines

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, consent s
under paragraph 1C(1) of the Placing Guidelines to permit certain Offer Shares to be placed to
connected clients of connected distributor s under the International Offering pursuant to the Placing
Guidelines. Details of the placement to connected client s are set out below. The allocation of Offer
Shares to such connected client s is in compliance with all the conditions under the consent s granted
by the Stock Exchange. Please also refer to the section headed “Allotees with Consent s Obtained” in
this announcement for details.

Connected Clients holding the beneficial interest of the Offer Shares on behalf of independent third
parties

Connected
Distributor
Connected
Client
Relationship
with the
Connected
Distributor
Whether the
connected
client will
hold
beneficial
interests of
Offer Shares
on a -non
discretionary
or
discretionary
basis for
independent
third parties
Number of
Offer
Shares to be
allocated to
the
connected
client
Appropriate
percentage
of total
number of
Offer
Shares
(assuming
the Over -
allotment
Option is
not
exercised)
Approximate
percentage
of total
issued share
capital in the
Company
upon Listing
(assuming
the Over -
allotment
Option is not
exercised)
CLSA
Limited
(“CLSA”)
CSI CSI is a
member of
the same
group of
companies as
CLSA
Non-
discretionary
basis
213,000 1.57% 0.29%
Shanxi
Securities
International
Limited
("SSI") Note 2
SSIAM Both SSI and
SSIAM are
ultimately
controlled by
Shanxi
Discretionary
basis
244,400 1.80% 0.33%


--- page 17 ---
17

Connected
Distributor
Connected
Client
Relationship
with the
Connected
Distributor
Whether the
connected
client will
hold
beneficial
interests of
Offer Shares
on a -non
discretionary
or
discretionary
basis for
independent
third parties
Number of
Offer
Shares to be
allocated to
the
connected
client
Appropriate
percentage
of total
number of
Offer
Shares
(assuming
the Over -
allotment
Option is
not
exercised)
Approximate
percentage
of total
issued share
capital in the
Company
upon Listing
(assuming
the Over -
allotment
Option is not
exercised)
Securities
International
Financial
Holdings
("SSIFH").

Notes:

(1) CSI will act as the single counterparty of a back-to-back total return swap transaction (the “CSI Back
to-back TRS”) to be entered into by CSI in connection with a total return swap order (the “CSI Client
TRS”) placed and fully funded by its ultimate clients (the “CSI Ultimate Client(s)”), by which CSI will
pass the full economic exposure of the Offer Shares placed to CSI to the CSI Ultimate Clients. CSI will
hold the beneficial interest of the Offer Shares on behalf of the CSI Ultimate Client on a non -
discretionary basis. The CSI Ultimate Client may exercise an early termination right to early terminate
the CSI Client TRS at any time from the trade date of the CSI Client TRS which should be on or after
the date on which the Offer Shares are listed on the Stock Exchange. Upon the final maturity or
termination of the CSI Client TRS by the CSI Ultimate Client, CSI will dispose of the Offer Shares on
the secondary market and the CSI Ultimate Client will rece ive a final termination amount of the CSI
Back-to-back TRS which should have taken into account all the economic returns or economic loss in
relation to the Offer Shares and the fixed amount of transaction fees of the CSI Back-to-back TRS and
the CSI Client TRS. CSI will not exercise the voting right of the Offer Shares during the terms of the
CSI Back-to-back TRS. CSI is not a collective investment scheme which is not authorized by the SFC,
or is expected to hold the Offer Shares on behalf of such scheme.

The details of the CSI Ultimate Clients are as follows:

Name of CSI Ultimate
Client
Limited Partner/
Shareholding
holding 30% or
more in the CSI
Ultimate Clients
Fund Manager/
General Partner
Ultimate beneficial
owners of Fund
Manager / General
Partner
Liangpai Exclusive Fund
No. 43 Private Securities
Investment Fund (量派
專享四十三號私募證券
投資基金)
Sun Lin (孫林) Shanghai QuantPi
Investment Limited
(上海量派投資管理有限
公司)
Sun Lin (孫林) and Yu
Hang (余航)
Canaan China Flagship
Fund
Liang Hao N/A N/A
Hover4pi Fund I OFC N/A Hover4pi Capital He Hui


--- page 18 ---
18

Name of CSI Ultimate
Client
Limited Partner/
Shareholding
holding 30% or
more in the CSI
Ultimate Clients
Fund Manager/
General Partner
Ultimate beneficial
owners of Fund
Manager / General
Partner
Management
Tongyi Taoli No. 1
Private Securities
Investment Fund (通怡
桃李1號私募證券投資
基金)
Wang Jing (王靜) Shanghai Tongyi
Investment Management
Co., Ltd. (上海通怡投資
管理有限公司)
Chu Yibo (儲貽波)
Tongyi Taoli No. 10
Private Securities
Investment Fund (通怡
桃李10號私募證券投資
基金)
N/A Shanghai Tongyi
Investment Management
Co., Ltd. (上海通怡投資
管理有限公司)
Chu Yibo (儲貽波)
Heyi Xuehu No. 1
Private Securities
Investment Fund (合易
雪湖1號私募證券投資
基金)
N/A Beijing Heyi Yingtong
Asset Management Co.,
Ltd (北京合易盈通資產
管理有限公司)
Liu Zhe (劉喆) and Liu
Yang (劉洋)
Evolution Darwin
Shangshan No. 3 Private
Securities Investment
Fund (進化論達爾文上
善三號私募證券投資基
金)
N/A Hainan Evolution Asset
Management Co., LTD (海
南進化論私募基金管理
有限公司)
Wang Yiping (王一平)
Heijing Capital
Management Co., Ltd.
(黑晶資本管理有限公
司)
Li Chuxin (李出新)
and Shao Yukai (邵
宇開)
N/A N/A

To the best knowledge of CSI and after making all reasonable enquiries, each of the CSI Ultimate
Clients is an independent third party of the Company, its subsidiaries and substantial shareholders,
CSI, CLSA and the companies which are members of the same group of CLSA.

(2) SSI is a non-syndicate distributor in relation to the Global Offering. In relation to the subscription,
SSIAM shall hold the Offer Shares in its capacity as the discretionary fund manager on behalf of its
investor holding over 30% interest  (the " SSIAM Ultimate Client "). SSIAM is not a collective
investment scheme which is not authorised by the SFC or is expected to hold the Offer Shares on
behalf of such scheme. The SSIAM Ultimate Client is Zeng Jinjing (曾金晶). To the best knowledge
of SSIAM, the SSIAM Ultimate Client is an independent third party of the Company, its subsidiaries,
its substantial shareholders, SSIFH and the companies which are members of the same group of
companies as SSIFH.

Placing to a close associat e of existing Shareholder s as placee with a prior consent under
paragraph 1C(2) of the Placing Guidelines

The Company has applied to the Stock Exchange, and the Stock Exchange has granted, a consent under
paragraph 1C(2) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the
International Offering to Wealth Shine, a close associate of Ruiji Phase III and Ruiji Phase X  (the
"Existing Shareholders "), each an existing Shareholder, on the following grounds  which are
consistent with the conditions as set out in Paragraph 18 of Chapter 2.3 and Chapter 4.15 of the Guide


--- page 19 ---
19

for New Listing Applicant:

(1) the Company will comply with the public float requirement under Rule 19A.13A of the Listing
Rules and the free float requirement under Rule 19A.13C of the Listing Rules;

(2) no preference in allocation has been, nor will be, given to Wealth Shine as a placee  by virtue
of being a close associate of the Existing Shareholders in any allocation in the placing tranche
of the Global Offering;

(3) each of the Company, the Sole Sponsor and the Sole Overall Coordinator has provided the
Stock Exchange with written confirmations in accordance with Chapters 2.3 and 4.15 of the
Guide; and

(4) the relevant information in respect of the allocation to Wealth Shine as a placee  has been
disclosed in this allotment results announcement.

Such allocation of Offer Shares is in compliance with all the conditions under the consent granted by
the Stock Exchange.


--- page 20 ---
20

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong
Kong Securities Clearing Company Limited take no responsibility  for the contents of this
announcement, make no representation as to its accuracy or completeness and  expressly disclaim
any liability whatsoever for any loss howsoever arising from or in reliance  upon the whole or any
part of the contents of this announcement.
This announcement is not for release, publication, distribution, directly or indirectly, in or into the
United States (including its territories and possessions, any state of the United States and the District
of Columbia). This announcement does not const itute or form a part of any offer or solicitation to
purchase or subscribe for securities in the United States. The securities mentioned herein have not
been, and will not be, registered under the United States Sec urities Act of 1933, as amended (the
“U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant
to an exemption from the registration requirements of the U.S. Securities Act and in compliance with
any applicable state securities laws, or outside the United States unles s in compliance with
Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United
States.
The Offer Shares are being offered and sold outside the United States in offshore transactions in
reliance on Regulation S under the U.S. Securities Act.
This announcement is for information purposes only and does not constitute an invitation or offer to
acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential
investors should read the Prospectus dated June 12, 2026 issued by HJ Science Co., Ltd. for detailed
information about the Global Offering described below before deciding whether or not to invest in
the H Shares thereby being offered.
*Potential investors of the Offer Shares should note that the Sole Sponsor  and the Sole Overall
Coordinator (acting in such capacity and as the Underwriter and the Capital Market Intermediary)
shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with
immediate effect upon the occurrence of any of the events set out in the section headed
“Underwriting — Underwriting Arrangements and Expenses  — Hong Kong Public Offering —
Hong Kong Underwriting Agreement — Grounds for Termination” in the Prospectus at any time
prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on June
23, 2026).


--- page 21 ---
21
PUBLIC FLOAT AND FREE FLOAT
Immediately after the completion of the Global Offering (before any exercise of the Over-allotment
Option), an aggregate of 39,106,162 H Shares, representing 53.13% of the total issued Shares upon
the Listing which is higher than the prescribed percentage of H Shares required to be held in public
hands of 25% under Rule 19A.13A(1) of the Listing Rules, will be counted towards the public
float. Hence, the Company will be able to comply with Rule 19A.13A(1) of the Listing Rules.
Pursuant to the applicable PRC law, within the 12 months following the Listing Date, all existing
Shareholders (including the Pre-IPO Investors) cannot dispose of any of the Shares held by them.
Pursuant to the relevant cornerstone investment agreements, each Cornerstone Investor has agreed
to a lock-up period of six months following the Listing Date. As such, the H Shares held by the
existing Shareholders and the Cornerstone Investors upon the Listing shall not be counted towards
the free float of the H Shares of the Company at the time of Listing. Based on the Offer Price of
HK$81.80 per Offer Share, the expected market value of the H Shares held by the public and not
subject to disposal restrictions exceeds HK$600,000,000. Therefore, the Company will comply
with the free float requirement under Rule 19A.13C(1)(b) of the Listing Rules.
The Directors confirm that, immediately following completion of the Global Offering (assuming
the Over-allotment Option is not exercised): (i) no placee will, individually, be placed more than
10% of the enlarged issued share capital of the Company immediately after the Global Offering;
(ii) there will not be any new substantial Shareholder under the Listing Rules immediately after the
Global Offering; (iii) the three largest public shareholders of the Company do not hold more than
50% of the H shares in public hands at the time of the Listing in compliance with Rules 8.08(3)
and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the
Listing in compliance with Rule 8.08(2) of the Listing Rules.
COMMENCEMENT OF DEALINGS
The H Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, June
23, 2026 (Hong Kong time), provided that the Global Offering has become unconditional and the
right of termination described in the section headed “Underwriting
–  Underwriting Arrangements
and Expenses –  Hong Kong Public Offering –  Hong Kong Underwriting Agreement –  Grounds for
Termination ” in the Prospectus has not been exercised. Investors who trade the H Shares on the
basis of publicly available allocation details prior to the receipt of H Share certificates or prior to
the H Share certificates becoming valid evidence of title do so entirely at their own risk.
Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Tuesday, June
23, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange
will commence at 9:00 a.m. on Tuesday, June 23, 2026 (Hong Kong time). The H Shares will be
traded in board lots of 100 H Shares each, and the stock code of the H Shares will be 6132.
By order of the Board
HJ Science Co., Ltd.
Dr. Ji Jianxin
Executive Director, chairman of the Board,
chief executive officer and general manager
Hong Kong, June 22, 2026
As at the date of this announcement, the executive Directors are Dr. Ji Jianxin, Mr. Yang Xiangyu,
Mr. Wu Zhen and Ms. Zhang Yao; the non-executive Directors are Ms. Geng Xueli, Mr. Du
Jiangbo, Mr. Wang Junfeng and Mr. Zhang Zhiyong; and the independent non-executive Directors
are Mr. Wong Jovi Chi Wing, Mr. Jiang He, Ms. Lin Fangzhu and Mr. Liu Zhe.
